Urologie最新文献_第9页

[Pediatric testicular tumors]. [小儿睾丸肿瘤]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1007/s00120-025-02601-w

Pia Paffenholz

{"title":"[Pediatric testicular tumors].","authors":"Pia Paffenholz","doi":"10.1007/s00120-025-02601-w","DOIUrl":"10.1007/s00120-025-02601-w","url":null,"abstract":"Background: Testicular tumors are rare in childhood but differ significantly from adult forms in terms of etiology, histology, and prognosis. Early diagnosis and appropriate treatment are crucial for the prognosis and quality of life of affected children.Objective: The aim of this article is to provide an overview of the etiology, classification, clinical presentation, diagnostic tests, and treatment of pediatric testicular tumors.Materials and methods: This article is based on an analysis of current literature.Results: Pediatric testicular tumors are benign in 60-75% of cases, most commonly teratomas or Leydig cell tumors. Malignant tumors such as yolk sac tumors are rare and show low metastatic potential. Diagnostics include ultrasound, tumor markers (AFP, hCG, LDH), and imaging (MRI, CT). Treatment consists of organ-sparing surgery in suspected benign cases and orchiectomy in malignant cases. Chemotherapy is reserved for metastatic tumors. In localized stage I disease, surveillance is often sufficient.Conclusion: Pediatric germ cell tumors differ from adult testicular tumors in terms of incidence, malignancy, and histology. Treatment decisions should always be made within an interdisciplinary framework.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"660-663"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pediatric urology-common issues of the external genitalia in boys]. [小儿泌尿学-男孩外生殖器的常见问题]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-05-26 DOI: 10.1007/s00120-025-02599-1

Annette Schröder

引用次数: 0

[Boys' consultation-the urologist as a boys' physician]. [男孩咨询-泌尿科医生作为男孩的医生]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-06-26 DOI: 10.1007/s00120-025-02602-9

Joachim Steffens, Petra Anheuser, Jennifer Kranz

引用次数: 0

[Editorial]. [编辑]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-06-26 DOI: 10.1007/s00120-025-02626-1

Axel Heidenreich

引用次数: 0

[Successful implementation of screening for urothelial carcinoma of the upper and lower urinary tract-a critical evaluation of urine-based lateral flow tests]. 【成功实施上、下尿路尿路上皮癌筛查——基于尿侧流试验的关键评价】。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-05-21 DOI: 10.1007/s00120-025-02606-5

Thorsten H Ecke

引用次数: 0

[Stones in the lower pole and their treatment]. [下极结石及其治疗]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-06-23 DOI: 10.1007/s00120-025-02577-7

F Abd Ali, P Vincze, T R W Herrmann, C Netsch, B Becker, G Hatiboglu, R Homberg, K Lehrich, A Miernik, P Olbert, D S Schöb, J Herrmann, J A Gross, L Lusuardi, Karl-Dietrich Sievert

{"title":"[Stones in the lower pole and their treatment].","authors":"F Abd Ali, P Vincze, T R W Herrmann, C Netsch, B Becker, G Hatiboglu, R Homberg, K Lehrich, A Miernik, P Olbert, D S Schöb, J Herrmann, J A Gross, L Lusuardi, Karl-Dietrich Sievert","doi":"10.1007/s00120-025-02577-7","DOIUrl":"10.1007/s00120-025-02577-7","url":null,"abstract":"The most frequent initial clinical symptom is flank pain, which occurs in approximately half of affected patients with stones of the upper urinary tract. Of these patients approximately half require treatment and 50% will again have new stones in the future. Only 8% of urinary stones are clinically inapparent with 25-50% of the stones located in the lower calyx group and are incidentally discovered during the diagnostics of symptomatic stones. Stones in the lower calyx are more difficult to treat than other kidney stones due to the localization and the resulting access possibilities. The treatment must therefore be planned and carried out individually according to the available treatment options. Since the development of modern flexible ureterorenoscopes (URS) retrograde stone removal, which has few complications, has been highly valued in the treatment of stones of the lower calyx due to the desired primary stone clearance rates. Limiting factors are the longer treatment times for large stone masses and the considerable material costs. Furthermore, the various forms of percutaneous nephrolitholapaxy provide additional methods for the treatment of larger lower caliceal stones.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"715-724"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144477020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Invisible in the culture of remembrance in medicine? The Dresden-based urologist and venereologist Dora Gerson (1884-1941) was persecuted because of her Jewish heritage]. [在医学的记忆文化中是隐形的？德累斯顿的泌尿科医生和性病专家多拉·格森（1884-1941）因为她的犹太血统而受到迫害。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.1007/s00120-025-02614-5

Julia Nebe, Matthis Krischel

{"title":"[Invisible in the culture of remembrance in medicine? The Dresden-based urologist and venereologist Dora Gerson (1884-1941) was persecuted because of her Jewish heritage].","authors":"Julia Nebe, Matthis Krischel","doi":"10.1007/s00120-025-02614-5","DOIUrl":"10.1007/s00120-025-02614-5","url":null,"abstract":"The history of urology is traditionally considered to be male-dominated. However, the field has never been exclusively \"male medicine\"-neither in terms of patients nor medical staff. This article highlights the life and work of Dresden-based physician Dora Gerson (1884-1941), one of the first German female specialists in urology and dermatovenereology, and draws attention to the widespread invisibility of women in the culture of memory of the field. Gerson studied medicine in Munich and Leipzig at the beginning of the 20th century and worked in both clinical and social medicine in the following years. In her Dresden practice, she combined urology, dermatology, and venereology, while also running a public counseling center for women with sexually transmitted diseases. In 1933, Gerson's health insurance license was revoked, and she was forced to close her practice. From 1940 onward, she worked as a Jewish \"medical practitioner\" at the horticultural school in Ahlem, Hannover. In September 1941, under increasing pressure from repression, she took her own life. Her biography exemplifies a dual marginalization: as a member of a structurally disadvantaged gender and as a victim of Nazi persecution. The article connects Gerson's life story with issues of gender, memory culture, and recognition practices in medicine. It demonstrates how professional cultural memory functions selectively and explores how social background, gender, and political circumstances influence visibility and oblivion in medical history. The reflection on Dora Gerson's history thus also represents a critically reflective culture of remembrance within urology.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"686-695"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144235396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Association of glitazones and bladder cancer: a rapid review]. [格列酮与膀胱癌的关系：快速回顾]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-03-11 DOI: 10.1007/s00120-025-02557-x

Laila Schneidewind, Barbara Sommerhalder, Dario Willi, Cindy Rönnau, Annemarie Uhlig, Bernhard Kiss

{"title":"[Association of glitazones and bladder cancer: a rapid review].","authors":"Laila Schneidewind, Barbara Sommerhalder, Dario Willi, Cindy Rönnau, Annemarie Uhlig, Bernhard Kiss","doi":"10.1007/s00120-025-02557-x","DOIUrl":"10.1007/s00120-025-02557-x","url":null,"abstract":"Background: Since the authorization of glitazones as oral antidiabetics, there has been a controversial debate as to whether they increase the risk of bladder cancer or accelerate its progression. Recent data have shown that glitazones can upregulate the expression of Nectin4.Objectives: These results make a renewed detailed examination of the topic unavoidable. Consequently, we conducted a rapid evidence analysis. The primarily aim was to identify systematic reviews investigating this relationship. Second, translational studies that describe the molecular biological background were identified.Materials and methods: A rapid evidence analysis was conducted with a literature search in MEDLINE via PubMed for the period July 2000 (first approval of glitazones in the European Union) to the date of the last search (15 July 2024).Results: The primary literature search yielded 860 hits and ultimately 14 studies were included. Of these, 6 were systematic reviews (5 including meta-analyses) and 8 were translational studies. In the reviews, the data situation regarding the association of glitazones with bladder cancer remains ambiguous, particularly due to the heterogeneity of the underlying studies and numerous confounding factors such as age or smoking history. Experimental evidence of a causal relationship between glitazones and bladder cancer could not be demonstrated. Two included studies even see a possible therapeutic benefit of the preparations in these patients.Conclusion: It remains unclear whether glitazones play a relevant role in the development of bladder cancer. The possible therapeutic benefit should be urgently investigated further.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"669-677"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Human papillomavirus (HPV) vaccination for cancer prevention]. [人乳头瘤病毒（HPV）疫苗预防癌症]。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-04-30 DOI: 10.1007/s00120-025-02597-3

Julius Benedikt Schneede, Peter Schneede

引用次数: 0

Metabolic evaluation of urolithiasis: a narrative review. 尿石症的代谢评价：叙述性回顾。

IF 0.5 4区医学

Urologie Pub Date : 2025-07-01 Epub Date: 2025-06-20 DOI: 10.1007/s00120-025-02617-2

Panagiotis Angelopoulos, Panagiotis Neofytoy, Stamatios Katsimperis, Panagiotis Triantafylloy, Ioannis Manolitsis, Michael Lardas, Titos Markopoulos, Ioannis Varkarakis, Lazaros Tzelves, Andreas Skolarikos

{"title":"Metabolic evaluation of urolithiasis: a narrative review.","authors":"Panagiotis Angelopoulos, Panagiotis Neofytoy, Stamatios Katsimperis, Panagiotis Triantafylloy, Ioannis Manolitsis, Michael Lardas, Titos Markopoulos, Ioannis Varkarakis, Lazaros Tzelves, Andreas Skolarikos","doi":"10.1007/s00120-025-02617-2","DOIUrl":"10.1007/s00120-025-02617-2","url":null,"abstract":"Urolithiasis is a common condition with high recurrence rates, often driven by metabolic abnormalities, dietary habits, and systemic disorders. Metabolic evaluation plays a key role in identifying modifiable risk factors such as hypercalciuria, hyperoxaluria, hypocitraturia, and hyperuricosuria. Despite its clinical value, metabolic evaluation remains underused in practice. This narrative review highlights the rationale, methods, and therapeutic implications of metabolic assessment in patients with recurrent or high-risk stone disease. The evaluation includes medical and dietary history, physical examination, blood and urine tests, 24‑h urine collections, and stone analysis. Tailored interventions-ranging from dietary advice to pharmacologic treatments such as thiazides, potassium citrate, and allopurinol-can reduce stone recurrence and prevent complications such as chronic kidney disease. Ongoing follow-up is essential to assess treatment response and modify strategies. Adherence to current guidelines and broader implementation of metabolic workup can significantly improve patient outcomes and reduce the global burden of stone disease.","PeriodicalId":29782,"journal":{"name":"Urologie","volume":" ","pages":"680-685"},"PeriodicalIF":0.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0